Study on safety and efficacy of granulocyte transfusion mobilized with G-CSF in related donor
Phase 1
- Conditions
- Severe neutropenic patients following alloHSCT or chemotherapy
- Registration Number
- JPRN-UMIN000014777
- Lead Sponsor
- Kansai Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Recipient: not expected to survive more than 30 days, self hematopoiesis is not expected to recover within 30 days. Donor: allergy aginst G-CSF, pregnant or possible to be pregnant, breast feeding, history of thrombosisi or have risk of thrombosis, splenomegaly, comorbidiy or history of interstitial pneumonia, history of cancer, comorbidities of cardiac, pulmonary, renal diseases to be treated, comorbidities of inflammatory, autoimmune diseases to be treated.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluate safety and efficacy in both donor and recipient
- Secondary Outcome Measures
Name Time Method Overall survival in recipient at 30 days after granulocyte transfusion